Enliven Therapeutics (ELVN) to Post Earnings on Wednesday

Enliven Therapeutics (NASDAQ:ELVN) is anticipated to announce its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect the company to announce earnings of ($0.3872) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:00 PM ET.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. On average, analysts expect Enliven Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Enliven Therapeutics Stock Performance

Shares of Enliven Therapeutics stock opened at $61.11 on Wednesday. The firm has a 50-day simple moving average of $47.45 and a two-hundred day simple moving average of $39.05. The company has a market cap of $3.72 billion, a P/E ratio of -36.59 and a beta of 0.27. Enliven Therapeutics has a fifty-two week low of $14.78 and a fifty-two week high of $61.29.

Analyst Ratings Changes

ELVN has been the topic of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. Stifel Nicolaus upped their price target on Enliven Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. The Goldman Sachs Group increased their price target on Enliven Therapeutics from $59.00 to $67.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Mizuho raised their price objective on Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a report on Tuesday, June 2nd. Finally, Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $70.50.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction that occurred on Friday, July 17th. The stock was sold at an average price of $52.64, for a total transaction of $316,787.52. Following the completion of the transaction, the chief financial officer owned 46,054 shares of the company’s stock, valued at $2,424,282.56. This represents a 11.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $50.49, for a total value of $504,900.00. Following the transaction, the director directly owned 41,884 shares of the company’s stock, valued at $2,114,723.16. The trade was a 19.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 32,036 shares of company stock worth $1,430,676 over the last ninety days. 3.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Enliven Therapeutics

Several large investors have recently made changes to their positions in ELVN. BNP Paribas Financial Markets increased its position in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in Enliven Therapeutics in the 4th quarter valued at $83,000. Quantbot Technologies LP boosted its stake in Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Enliven Therapeutics by 194.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock worth $106,000 after purchasing an additional 3,490 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Enliven Therapeutics during the fourth quarter worth $191,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.